Research Overview Understanding the Triple-Receptor Mechanism Retatrutide is the first clinically advanced peptide engineered for balanced agonism at three class B G protein-coupled receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
For pens with a button, press and hold the injection button until the dose indicator returns to zero or the pen clicks to confirm the full dose has been delivered
In addition, a large number of clinical studies have shown that GLP-/GIP dual agonists can reduce LFC, VAT, and body weight, and have an improvement effect on both NAFLD and NASH [131,132]
CAROLYN BRAMANTE: Yeah, it's very interesting
While all of these potential benefits are exciting, experts said they need much more study, and even then, whether they might ever be utilized as a treatment for schizophrenia, for example, would depend on a number of factors: how much and how consistently they work, as well as how they compare to treatments that are already available
Asakawa A, Inui A, Yuzuriha H, et al